How do COPD comorbidities affect ICU outcomes?

Background and aim: Chronic obstructive pulmonary disease (COPD) patients with acute respiratory failure (ARF) frequently require admission to the intensive care unit (ICU) for application of mechanical ventilation (MV). We aimed to determine whether comorbidities and clinical variables present at ICU admission are predictive of ICU mortality.

Methods: A retrospective, observational cohort study was performed in a tertiary teaching hospital's respiratory ICU using data collected between January 2008 and December 2012. Previously diagnosed COPD patients who were admitted to the ICU with ARF were included. Patients’ demographics, comorbidities, body mass index (BMI), ICU admission data, application of noninvasive and invasive MV (NIV and IMV, respectively), cause of ARF, length of ICU and hospital stay, and mortality were recorded from their files. Patients were grouped according to mortality (survival versus non-survival), and all the variables were compared between the two groups.

Results: During the study period, a total of 1,013 COPD patients (749 male) with a mean age (standard deviation) of 70±10 years met the inclusion criteria. Comorbidities of the non-survival group (female/male, 40/131) were significantly higher compared with the survival group (female/male, 224/618): arrhythmia (24% vs 11%), hypertension (42% vs 34%), coronary artery disease (28% vs 11%), and depression (7% vs 3%) (P<0.001, P<0.035, P<0.001, and P<0.007, respectively). Logistic regression revealed the following mortality risk factors: need of IMV, BMI <20 kg/m², pneumonia, coronary artery disease, arrhythmia, hypertension, chronic hypoxia, and higher acute physiology and chronic health evaluation II (APACHE II) scores. The respective odds ratios, confidence intervals, and P-values for each of these were as follows: 27.7, 15.7–49.0, P<0.001; 6.6, 3.5–412.7, P<0.001; 5.1, 2.9–8.8, P<0.001; 2.9, 1.5–5.6, P<0.001; 2.7, 1.4–5.2, P<0.003; 2.6, 1.5–4.4, P<0.001; 2.2, 1.2–3.9, P<0.008; and 1.1, 1.03–1.11, P<0.001.

Conclusion: Patients with severe COPD and cardiac comorbidities and cachexia should be closely monitored in ICU due to their high risk of ICU mortality.

Keywords: comorbidity, chronic obstructive pulmonary disease, intensive care unit

Introduction

The prevalence of chronic obstructive pulmonary disease (COPD) ranges from 8% to 20% worldwide.1 Decelerated disease progression, increased quality of life, and reduced rates of hospitalization have been achieved with current COPD treatment approaches.2-4 However, intensive care unit (ICU) admission may be required due to disease progression, exacerbation, and respiratory failure. Priority application of noninvasive mechanical ventilation (NIV) is associated with a significantly decreased ICU mortality of COPD patients.5 Despite advances, ICU
treatment outcomes are not always successful with NIV treatment; patient comorbidities may play an important role in survival.

Cardiovascular diseases, diabetes mellitus (DM), hypertension, osteoporosis, psychiatric diseases (anxiety and depression), metabolic syndrome, lung cancer, and infections are defined as COPD-related comorbidities. Although the need for ICU admission is thought to be due to disease progression, there is no clear relationship with these comorbidities and ICU demand. The presence of comorbidities are known to be associated with a detersiorated course of COPD; however, there is limited data regarding the reasons for respiratory failure in COPD patients and the effect of these comorbidities on ICU outcome.

This study was designed to investigate the causes of mortality in COPD patients admitted to the ICU, the presence of comorbidities, and their effect on mortality. The research was conducted in the respiratory ICU of a tertiary chest disease training and research hospital in which 1,050 patients with respiratory failure were followed annually.

Methods
We designed a retrospective, observational, cohort study in a 22-bed, level III ICU of a tertiary teaching hospital for chest diseases, thoracic surgery center between January 1, 2008 and December 31, 2012. This chest diseases center is a reference hospital for only the Anatolian Region of Turkey. During the study period, a total of eight intensivist specialists worked in the ICU, which they staffed 24 hours a day. The study was approved by the local ethics committee of Kartal Lutfi Kirdar Teaching and Research Hospital, Istanbul, Turkey. Ethical approval was in accordance with the Declaration of Helsinki. Due to the retrospective nature of the study design, informed consent was not obtained.

Patients
We included consecutive patients with previously diagnosed COPD who were admitted to our ICU due to acute respiratory failure (ARF). Previously COPD diagnoses were established by a physician who evaluated airflow obstruction on spirometry; those with forced expiratory volume in 1 second (FEV₁) of 70% predicted or less, and an FEV₁, and forced vital capacity ratio of 70% or less were determined to have COPD. Spirometry test data were not recorded from the patients’ charts. Spirometry testing was not performed for either confirmation or new diagnosis of COPD during ICU stay of patients. Only those patients who were admitted to the ICU for the first time with ARF were evaluated in case of recurrent admissions to the ICU during the study period. Patients were grouped based on ICU mortality (Figure 1).

Data
Demographics and reasons for ICU admission associated with ARF, such as sepsis/septic shock, pneumonia, pulmonary embolism, and pneumothorax, were recorded from the patients’ ICU files. Comorbidities, including DM, arrhythmia (ie, atrial fibrillation), hypertension, congestive heart failure, coronary artery disease (CAD), malignancy, and depression were also recorded, as were history of smoking, use of long-term oxygen therapy (LTOT), and long-term mechanical ventilation (MV) (NIV or invasive [IMV]) via tracheostomy. Acute physiology and chronic health evaluation II (APACHE II) scores were calculated as part of the patients’ ICU severity index and on admission to the ICU. Arterial blood gas (ABG) values at the time of ICU admission and discharge were recorded from the patients’ file. Serum C-reactive protein (CRP) levels, the application of NIV and/or IMV in the ICU, the lengths of ICU and hospital stays (days), and ICU mortality (mortality during the ICU stay) were recorded at ICU admission and discharge. Reasons for ICU admission were defined as infection (lower respiratory infection), pulmonary embolism, and pneumothorax, and also pneumonia-caused respiratory failure. Reasons for mortality were grouped as pneumonia, lower respiratory tract infection, lung cancer, severe sepsis/septic shock, multi-organ failure, myocardial infarction, and pulmonary embolism.

Definition
Hypoxic ARF was defined as the ratio of partial arterial oxygen pressure to inspired fractionated oxygen (PaO₂/FiO₂) <300 and partial arterial carbon dioxide pressure (PaCO₂) <45 mmHg. Hypercapnic/hypoxemic ARF was
defined as PaCO$_2$ >45 mmHg and PaO$_2$/FiO$_2$ <300, and hypercapnic ARF was PaCO$_2$ >45 mmHg and PaO$_2$/FiO$_2$ >300.$^{5,8}$ Patients with PaCO$_2$ =45 mmHg and patients with PaO$_2$/FiO$_2$ =300 are treated by only medical treatment. The definition of COPD exacerbation due to an infectious origin was defined by the presence of all three of Anthonisen’s criteria, as follows: worsening of dyspnea, increased volume of pulmonary secretions (endotracheal and sputum), and increased respiratory secretion purulence.$^{7,13}$

### Mechanical ventilation

Initially, NIV was applied to all COPD patients with hypercapnic respiratory failure except when absolutely contraindicated.$^{14-16}$ NIV contraindications were defined as 1) absolute respiratory arrest and unable to fit mask, and 2) relative, medically unstable (hypotensive shock, uncontrolled cardiac ischemia or arrhythmia, or uncontrolled copious upper gastrointestinal bleeding), agitation, uncooperativeness, inability to protect airway, impaired swallowing, excessive secretions not managed by clearance techniques, multiple (two or more) organ failure, and recent upper airway or upper gastrointestinal surgery.$^{14-16}$

NIV was provided in pressure assist-control mode with ICU mechanical ventilators via a double-tube circuit with a full-face mask. Pressure support (PS) was initially set at 8–10 cm H$_2$O and gradually increased to a maximum of 30 cm H$_2$O until the exhaled tidal volume was 5–7 mL/kg and guided by patient tolerance. Positive end-expiratory pressure was set at 5 cm H$_2$O and raised or lowered to treat hypoxemia or enhance patient comfort, respectively. FiO$_2$ was adjusted to maintain oxygen saturation (SaO$_2$) at 90%. NIV was applied intermittently for periods of 1–4 hours, and initial ABG samples were obtained at the end of the first hour. The duration of each session was determined by ABG value improvement, consciousness level, and patient compliance. The definition of NIV failure in hypercapnic patients was no pH improvement, no change or a rise in breathing frequency after 1–2 hours, and lack of cooperation. For hypoxic COPD patients, failure was considered as no, or a minimal, rise in PaO$_2$/FiO$_2$ after 1–2 hours ($<$200).$^{14}$ IMV was applied in the presence of absolute or relative contraindications for NIV, as mentioned above. The Richmond agitation sedation scale was used for infusion and assessment of the daily need for sedation.$^{17}$ When patients met the previously described criteria for weaning, the PS ventilation mode was used and gradually decreased (1–2 cm H$_2$O every 1–2 hours).$^{20}$ When the PS reached 8–10 cm H$_2$O and positive end-expiratory pressure was 0 or <5 cm H$_2$O, the patient progressed to spontaneous breathing trials using a T-piece with oxygen support. The T-piece trial duration was 30 minutes, after which the patients were extubated. NIV was then applied in cases of moderate respiratory distress if there was no contraindication.$^{18}$

### Bronchodilator and anti-inflammatory treatment in the ICU

A short-acting B$_2$ agonist (salbutamol, 100 µg per puff) and ipratropium bromide (100 µg/20 µg per puff) were given every 2–4 hours (4–10 puffs) via a metered dose inhaler chamber (Aerovent, Altech®; Altera Firm, Izmir, Turkey) when the patients were under NIV or IMV. A nebular form of salbutamol (2.5 mg/2.5 mL per nebul) was given every 15 minutes to 4 hours, or ipratropium bromide/salbutamol (0.5 mg/3.01 mg/2.5 mL per nebul) was given every 2–4 hours for patients breathing without MV support. Long-acting B$_2$ agonists were not used in COPD patients with ARF in the ICU. Intravenous methylprednisolone (40–60 mg) was given one to two times daily as an anti-inflammatory for those patients unable to take oral medications or with impaired gastrointestinal absorption. The steroid dose was gradually tapered and then discontinued over 7–10 days. Methylxanthines (theophylline and aminophylline) were not administered. All patients received oxygen for COPD, as well as medication to treat the underlying cause of ICU admission or ARF and comorbidities, such as antibiotics, antiarrhythmic drugs, or anticoagulant therapies.$^{19}$

### Statistical analysis

A descriptive analysis was performed to investigate patient demographics and ICU data. Groups were compared with Mann–Whitney U-tests or Student’s t-tests for nonparametric continuous or parametric continuous variables, respectively. Chi-square tests were employed for dichotomous variables. The median with interquartile range was employed for nonparametric continuous variables, and mean ± standard deviation was used for parametric continuous variables. Count and percentage were used when applicable. Binary logistic regression analyses were performed to predict COPD patient ICU mortality. We included the variables that were of statistical significance following univariate analyses in the model. A P-value <0.05 was accepted as statistically significant. The SPSS-20 portable package program was used to perform statistical analyses.

### Results

During the study period, a total of 3,992 patients were admitted to the ICU. After excluding patients who were
readmitted, 1,013 (25%) patients with COPD were included in the study. ICU mortality was observed in 171 (16.9%) cases (Figure 1). All patients were divided into two groups: survivors and non-survivors. The groups’ demographic and ICU data are summarized in Table 1. Both groups had similar gender ratios with male predominance. Survivors were significantly more overweight than non-survivors ($P<0.001$). Among the five comorbidities, hypertension was the most common in both groups. While the rates of DM were similar in both groups, the other comorbidities were significantly more frequent in non-survivors (Table 1). In addition, non-survivors had a significantly higher rate of home device use (LTOT, NIV) and were more likely to have been tracheostomized. APACHE II scores, $\text{PaO}_2/\text{FiO}_2$, bicarbonate ($\text{HCO}_3$) level in ABGs, and serum CRP values at ICU admission were significantly worse in non-survivors compared with survivors (Table 1). Infection was the major reason for ICU admission in both groups, and the presence of pneumonia was significantly higher in

<table>
<thead>
<tr>
<th>Table 1 Demographics and ICU data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Survivors</strong></td>
</tr>
<tr>
<td>n=842</td>
</tr>
<tr>
<td><strong>Demographics</strong></td>
</tr>
<tr>
<td>Female/male</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
</tr>
<tr>
<td>41–65 years</td>
</tr>
<tr>
<td>66–80 years</td>
</tr>
<tr>
<td>81 years and above</td>
</tr>
<tr>
<td>BMI, mean ± SD</td>
</tr>
<tr>
<td><strong>Comorbidities of groups, n (%)</strong></td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>CAD</td>
</tr>
<tr>
<td>Arrhythmia</td>
</tr>
<tr>
<td>DM</td>
</tr>
<tr>
<td>Malignancy</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td><strong>Reasons of ICU admission</strong></td>
</tr>
<tr>
<td>COPD exacerbations</td>
</tr>
<tr>
<td>Infection of LRT, n (%)</td>
</tr>
<tr>
<td>Pulmonary Embolism, n (%)</td>
</tr>
<tr>
<td>Pneumothorax, n (%)</td>
</tr>
<tr>
<td>Pneumonia, n (%)</td>
</tr>
<tr>
<td><strong>ABG values on the admission to the ICU</strong></td>
</tr>
<tr>
<td>$\text{PaO}_2/\text{FiO}_2$, median (25%–75%)</td>
</tr>
<tr>
<td>pH, mean ± SD</td>
</tr>
<tr>
<td>$\text{PaO}_2$ mmHg, median (25%–75%)</td>
</tr>
<tr>
<td>$\text{PaCO}_2$ mmHg, mean ± SD</td>
</tr>
<tr>
<td>$\text{HCO}_3$ mmol, mean ± SD</td>
</tr>
<tr>
<td>Respiratory failure</td>
</tr>
<tr>
<td>Hypoxemic, n (%)</td>
</tr>
<tr>
<td>Hypercarbic, n (%)</td>
</tr>
<tr>
<td>Mixed, n (%)</td>
</tr>
<tr>
<td>CRP on the admission to the ICU, median (25%–75%)</td>
</tr>
<tr>
<td>ICU hospitalization, n</td>
</tr>
<tr>
<td>Hospitalization, n</td>
</tr>
</tbody>
</table>

**Abbreviations:** ABG, arterial blood gas; APACHE II, acute physiology and chronic health evaluation II; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DM, diabetes mellitus; $\text{FiO}_2$, fraction of inspired oxygen; ICU, intensive care unit; IMV, invasive mechanical ventilation; LRT, lower respiratory tract; LTOT, long-term oxygen therapy; NIV, noninvasive mechanical ventilation; $\text{PaCO}_2$, partial arterial pressure of carbon dioxide; $\text{PaO}_2$, partial arterial pressure of oxygen; SD, standard deviation.
non-survivors (P<0.001) (Table 1). Both groups stayed in
the ICU for a similar number of days.

The comorbidity distributions for females and males
in each group are summarized in Table 2. Females in both
groups had significantly higher rates of DM, hypertension,
and depression. The prevalence rates of CAD and arrhythmia
were similar for both sexes and groups (Table 2).

Table 3 shows the body mass index (BMI) distributions
in both groups. A larger proportion of survivors were obese
(P<0.002). Hypertension was significantly more likely in
obese survivors (P<0.001) and non-survivors (P<0.010).
There were no differences in the rates of CAD and arrhyth-
mias in the different BMI subgroups among survivors and
non-survivors. A significantly higher rate of depression was
noted in lean non-survivor COPD patients.

Figure 2 shows the reasons for ICU mortality. Death in
one patient was attributable to multiple causes. The majority
of patients died due to pneumonia, while the least common
cause of death was pulmonary emboli.

The requirement for MV (either NIV or IMV) is shown
in Figure 3. None of the patients in the survivor group expe-
rienced NIV failure. Among the non-survivors, 109 initially
received NIV (n=109), and 56 NIV failure patients were
intubated to receive IMV. Two non-survivor patients with
only oxygen therapy were not intubated for IMV due to the
patients’ and family members’ wishes for end-stage treatment
for underlying diseases.

Among the non-survivors, exposure to biomass (mostly
using cow feces as home heating source in the Anatolian
villages) was only observed in females (n=21). Cigarette
smoking history as median packets per year was 40 (30–75)
and 50 (40–80) packs/year for female and male COPD
patients, respectively.

Figure 4 shows the MV demand and ICU outcome in
COPD patients with/without pneumonia in the ICU. The
mortality rate of pneumonia COPD patients with IMV was
two times greater than in those patients without pneumonia.

Logistic regression analysis was performed to predict
mortality among COPD patients in the ICU (Table 4). We
included the comorbidities and ICU variables recorded in
the logistic regression model. IMV application, BMI index
groups, pneumonia, and higher APACHE II score on admis-
sion to the ICU were not significant risk factors, whereas
CAD, hypertension, and chronic hypoxic respiratory failure
were found to be mortality risk factors in the ICU.

Figure 5 shows causal diagram for effect of confounding
comorbidities on COPD patients with respiratory failure
requiring IMV due to respiratory failure with confound-
ing by comorbidities (arrhythmias, hypertension, chronic
hypoxic respiratory failure, BMI ≤20, >20 kg/m²) and
presence of pneumonia.

**Discussion**

This study found that CAD, arrhythmia, and hypertension
were significant mortality predictors among the comorbid-
ities present in COPD patients admitted to ICU with ARF.
Pneumonia and lower respiratory tract infection were the top
causes of mortality in these patients. Other than pneumonia,
lower respiratory tract infection was the second most common
cause. Significant mortality predictors were the application of
IMV, a high APACHE II score, admission with pneumonia,
BMI ≤20, >20 kg/m², and chronic hypoxemic respiratory
failure.

**Sex and ICU mortality**

The ICU admission and mortality rates were lower in female
COPD patients. In a 2012 study conducted by Alaithan et al20
119 COPD patients admitted to ICU were included; 37%
were female, and there were no significant mortality differ-
ences between the sexes. Antonelli Incalzi et al21 carried out
a 5-year follow-up study involving 270 COPD patients and
reported that 17% were female. In our study, the population
was 26% female, and the mortality rates were similar between
the sexes. Additionally, biomass exposure was more common

---

**Table 2 Comorbidity distribution by sex in both groups**

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Survivors, n=842</th>
<th>Non-survivors, n=171</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female n=224</td>
<td>Male n=618</td>
</tr>
<tr>
<td>DM, n (%)</td>
<td>60 (43.2)</td>
<td>79 (56.8)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>107 (37.8)</td>
<td>175 (62.2)</td>
</tr>
<tr>
<td>CAD, n (%)</td>
<td>23 (24.5)</td>
<td>71 (75.5)</td>
</tr>
<tr>
<td>Arrhythmia, n (%)</td>
<td>31 (33.7)</td>
<td>62 (66.3)</td>
</tr>
<tr>
<td>Malignancy, n (%)</td>
<td>5 (22.7)</td>
<td>17 (77.3)</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>10 (41.7)</td>
<td>14 (58.3)</td>
</tr>
</tbody>
</table>

**Note:** Percentages are calculated from the sum of both females and males in each survivors or non-survivors group.

**Abbreviations:** CAD, coronary artery disease; DM, diabetes mellitus.
than socioeconomic status in females, which is in accordance with socioeconomic status in Turkey. Some studies have reported higher incidence rates of comorbidities associated with COPD in females or males.22–24 The TORCH study,25 which provided important data on COPD mortality, showed that comorbidities and mortality rates were similar between the sexes. In our study, we noted significantly higher incidence rates of DM, hypertension, depression, and arrhythmia in female populations; however, there was no sex difference for CAD. When comparing rates of mortality, DM, hypertension, and depression, we found that they were significantly higher in women. There were no sex differences for the prevalence rates of CAD and arrhythmia.

**Age and ICU mortality**

In a systematic review of 28 studies investigating risk factors for mortality of COPD patients in the ICU, the average age of the patients was reported to range from 57 to 72 years.29–31 In two of these well-designed studies with large sample sizes (n=3,752 and n=1,009), age was not identified as a mortality predictor. The two studies reported the mean age and mortality rates of these studies were 67.8 years and 38.3%, 70.2 years and 7.8%, respectively.29,30 The mean age and mortality rate in the present study were 70 years and 17%. There were no differences between survivor or non-survivor groups in our study for age.

**APACHE II score and ICU mortality**

In the systematic review using the APACHE II score as a mortality predictor and investigating COPD mortality,26 one study reported a low APACHE II score of 13 and 37% mortality, whereas another study described a high APACHE II score of 23.8 and 41% mortality.29,30 In our study, the mean APACHE II score was 20.4, and the mortality rate was 17%. Mean APACHE II score was significantly higher in the non-survivor group in our study.

**Comorbidity and ICU mortality**

Cardiovascular comorbidities (hypertension, CAD, arrhythmia, and heart failure) are the most common comorbidities of COPD. In our study, the rates for hypertension, CAD, and arrhythmia were 35%, 14%, and 13%, respectively. Mortality is reportedly increased in the presence of comorbid cardiovascular diseases.23,31 In their study of 20,296 COPD

---

**Table 3 BMI distributions with comorbidities by group**

<table>
<thead>
<tr>
<th></th>
<th>Survivors, n=842</th>
<th>Non-survivors, n=171</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI ≤20</td>
<td>n=114</td>
<td>n=58</td>
</tr>
<tr>
<td>BMI &gt;20–30</td>
<td>n=461</td>
<td>n=72</td>
</tr>
<tr>
<td>BMI &gt;30</td>
<td>n=166</td>
<td>n=18</td>
</tr>
<tr>
<td>DM, n (%)</td>
<td>10 (8)</td>
<td>5 (20.0)</td>
</tr>
<tr>
<td>HT, n (%)</td>
<td>15 (5.9)</td>
<td>14 (24.1)</td>
</tr>
<tr>
<td>CAD, n (%)</td>
<td>10 (11.9)</td>
<td>8 (22.2)</td>
</tr>
<tr>
<td>Arrhythmia, n (%)</td>
<td>6 (7.0)</td>
<td>11 (31.4)</td>
</tr>
<tr>
<td>Malignancy, n (%)</td>
<td>3 (15.0)</td>
<td>7 (35.0)</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>8 (34.8)</td>
<td>9 (31.4)</td>
</tr>
<tr>
<td>BMI 20–30</td>
<td>n=842</td>
<td>n=171</td>
</tr>
<tr>
<td>BMI &gt;30</td>
<td>n=171</td>
<td>n=171</td>
</tr>
</tbody>
</table>

**Note:** Percentages are calculated from the sum of both females and males in each survivors or non-survivors group.

**Abbreviations:** BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; HT, hypertension.
patients, Mannino et al.23 found DM and hypertension incidences of 12.7% and 40.1%, respectively. They found an overall 5-year mortality of 5.9%, which was significantly increased by DM and cardiovascular comorbidities. Almagro et al.31 assessed comorbidities in 398 COPD patients and reported that the most frequent were hypertension, DM, and CAD, with respective incidences of 55%, 26%, and 17%. In another study, the rates of hypertension and CAD were 28% and 10%, respectively, and right ventricular hypertrophy was found to be a risk factor for mortality.21 In the present analysis, hypertension was the most frequent cardiac comorbidity (42%), and the CAD and arrhythmia incidence rates were 22% and 24%, respectively. Notably, CAD and arrhythmia were twice as common in non-survivor COPD patients. We determined that CAD increased ICU mortality 2.9-fold, while arrhythmia and hypertension increased mortality 2.7- and 2.2-fold, respectively.

Although diabetes is one of the most frequently observed comorbidities in COPD patients, only about 10% of diabetic patients have COPD.6,32,33 Antonelli Incalzi et al. reported a 14% incidence of DM in COPD patients. Mannino et al.23 found that COPD patients with diabetes and cardiovascular comorbidities had higher rates of hospitalization and mortality. In our study, the rate of DM was similar (17%), but there was no statistically significant difference in terms of mortality between COPD patients with and without DM.

**BMI and ICU mortality**

BMI is included in the BODE (BMI, airflow obstruction, dyspnea, exercise capacity) mortality index due to increased

---

### Table 4 Mortality in ICU – logistic regression analysis of COPD patients

<table>
<thead>
<tr>
<th></th>
<th>Odds ratio</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMV</td>
<td>27.71</td>
<td>15.67–49.03</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI ≤20 kg/m²</td>
<td>6.63</td>
<td>3.45–12.74</td>
<td>0.001</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>5.09</td>
<td>2.96–8.76</td>
<td>0.001</td>
</tr>
<tr>
<td>in ICU admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD</td>
<td>2.92</td>
<td>1.52–5.58</td>
<td>0.001</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>2.70</td>
<td>1.40–5.22</td>
<td>0.003</td>
</tr>
<tr>
<td>Chronic hypoxic RF</td>
<td>2.60</td>
<td>1.33–4.40</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.17</td>
<td>1.22–3.85</td>
<td>0.008</td>
</tr>
<tr>
<td>APACHE II score on ICU admission</td>
<td>1.07</td>
<td>1.03–1.11</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Abbreviations:** APACHE II, acute physiology and chronic health evaluation II; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; RF, respiratory failure.

---

### Figure 4 Mechanical ventilation demand and ICU outcome in COPD patients with/without pneumonia in the ICU.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, noninvasive mechanical ventilation.

---

### Figure 5 Causal diagram for the effect of confounding comorbidities on COPD patients with respiratory failure requiring IMV.

**Abbreviations:** ARF, acute respiratory failure; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IMV, invasive mechanical ventilation; RF, respiratory failure.
mortality of COPD patients whose BMI score is $<40 \text{ kg/m}^2$.\textsuperscript{34} A recent study of 94 intubated patients investigated the effect of BMI on weaning trials.\textsuperscript{35} Within this study, patients were stratified into three groups (BMI $\leq 20 \text{ kg/m}^2$, lean; BMI 21–29 kg/m²; normal; BMI $\geq 30 \text{ kg/m}^2$, obese), and weaning in the lean group was difficult or even impossible.\textsuperscript{35} On the other hand, a study showing no correlation between weaning difficulty and BMI was also published.\textsuperscript{36} In our study, having a BMI $\leq 20 \text{ kg/m}^2$ increased ICU mortality 6.6-fold.

**Chronic hypoxemic respiratory failure and mortality**

Six studies have examined chronic hypoxemic respiratory failure and reported that LTOT use after ICU discharge is a mortality predictor.\textsuperscript{37–42} The strongest study among these was published in 2009; it followed 832 patients for 180 days, starting from the ICU, and reported a mortality rate of 37.9%. Chronic hypoxemic respiratory failure has also been found to be an independent mortality predictor.\textsuperscript{37} In our study, the rate of LTOT use was 39.3% in all patients and 57.3% in the mortality group. Chronic respiratory failure was found to increase ICU mortality 2.6-fold.

**Pneumonia and ICU mortality**

Although the risk of pneumonia in COPD mortality attracted attention due to the TORCH (towards a revolution in COPD health) study, conflicting results have been reported elsewhere.\textsuperscript{25,26} One of the four studies that reported that pneumonia is not a factor for ICU mortality determined that the presence of pulmonary infiltrates were associated with the terminal stage of COPD and mortality.\textsuperscript{30,43–45} However, Wildman et al\textsuperscript{27} indicated in their well-designed study that the presence of pneumonia was strongly correlated with ICU mortality of COPD patients. Results from a recent study conducted in Turkey described the mortality of patients diagnosed with community-acquired pneumonia at ICU admission.\textsuperscript{44} We found a five-fold mortality increase in patients with pneumonia. Culture specimens were taken from 80% of patients, and 75% were positive. Almost all the pathogens isolated from cultures were antibiotic resistant, which may be due to frequent and chronic use of antibiotics and hospitalizations. In a Turkish multicenter study, culture positivity was detected in 20% of cases, and resistant pathogens were noted in 70% of these patients.\textsuperscript{45} We observed fewer resistant pathogens compared with that study; however, Cilli et al\textsuperscript{45} did not report the rate of resistant pathogens among the 80% of patients for whom culture samples were not collected. In our study, the presence of pneumonia was found to predict mortality. Cilli et al\textsuperscript{45} indicated that application of IMV in COPD patients with pneumonia increased mortality 1.6-fold, while NIV application decreased the mortality rate by 72%. In the subanalysis of the two groups concerning the presence of pneumonia, the need for IMV therapy was two times greater in patients with pneumonia. Also, the rates of IMV therapy and NIV failure were five times greater in patients with pneumonia who had received NIV as an initial treatment. Additionally, a 2.2-fold higher mortality was observed in COPD patients who received IMV therapy with pneumonia compared with patients on IMV therapy without pneumonia. A three-fold greater mortality rate was noted in patients treated with NIV who had pneumonia compared with patients without pneumonia. Considering these results, the presence of resistant pathogens that cause pneumonia is thought to increase ICU mortality in COPD patients.

**MV and ICU mortality**

Decreased hospital mortality of COPD patients with ARF who received NIV was reported in a meta-analysis that included 979 COPD patients from 14 studies.\textsuperscript{46} The intubation rate of patients with initial NIV treatment ranged from 9% to 56%, while the mean intubation rate was 35%. The relative risk of mortality ranged from 13% to 100%, with an average of 45%.\textsuperscript{46} In the same meta-analysis, length of hospital stay was significantly decreased (mean 1.9 days in ten studies) in patients who received NIV treatment.\textsuperscript{46} In our study, NIV was applied unless there were contraindications, and 8.2% of patients required intubation. The mortality rate was 7.7% in patients who received NIV, and these patients were terminal and did not want to be intubated. Notably, there was a 100% mortality rate in patients who were intubated after NIV failure. Overall, 11.7% of patients were intubated at the time of admission, and half of these patients died. A mortality risk analysis of our data showed that the need for IMV treatment increased mortality 28-fold.

**Septic shock, multiple organ failure, and mortality**

Exacerbation of COPD and pneumonia were previously reported as the most common reasons for mortality in patients with ARF who were admitted to the ICU.\textsuperscript{26,45,46} Data regarding the definition of sepsis and septic shock in COPD patients are limited. We investigated systemic inflammatory response syndrome and sepsis criteria in our study, and septic shock at admission was detected in half of the patients in the
non-survivor group. Multi-organ failure was observed in 75% of patients in the non-survivor group.

**ABG analysis and ICU mortality**

Although existing studies have indicated an increased requirement for IMV treatment below pH 7.25 during NIV treatment, other studies reported that NIV can be successful when safe monitoring in the ICU is possible. Deep acidosis on ABG analyses was not observed in our patients. There were no significant differences in PaCO$_2$ or pH values of patients in the two groups, but O$_2$ demand (PaO$_2$/FiO$_2$) and HCO$_3$ values were significantly lower in the non-survivor group. Messer et al$^{26}$ reported that HCO$_3$ levels <20 mmol were associated with increased mortality.

**CRP and mortality**

In a well-designed study conducted by Rammaert et al,$^{28}$ CRP was found to be a significant mortality predictor. Although we found that CRP was higher in the non-survivor group, it was not a mortality predictor in the logistic regression analysis.

**Limitations**

Our study was retrospective and carried out at a single center. However, we believe that the study provides valuable clinical information for assessing ICU outcomes of COPD patients, as the study population was large and disease specific. COPD severity and spirometry results were not recorded, and the presence of osteoporosis was not recorded because there were no objective diagnostic test results on file. Missing data collection was not possible for the mortality group given the study’s retrospective nature. Nevertheless, the radiological and clinical findings of patients were consistent with COPD.

**Conclusion**

Nutrition protocol regulation is useful for improving the quality of life of COPD patients and their family. Follow-up of spirometry with BMI measurements and pulmonary rehabilitation are recommended for COPD patients who are admitted to the ICU with ARF. Because the presence of CAD and arrhythmia increase ICU mortality, it is recommended that the target SaO$_2$ for these patients should be >92. NIV can be risky for patients with hypoxia-induced arrhythmia, and treatments must be performed to address the underlying cause. Common reasons for COPD patient ICU admission are infection and the presence of resistant pathogens. Because these factors increase mortality, infection treatment protocols and rational antibiotic use should be planned. Data from this study and mortality predictors for COPD patients in the ICU will be helpful for identifying new treatment modalities. Finally, this study is important to determine the significance of long-term nutrition protocols, arrhythmia diagnosis/treatment, and rational antibiotic use in COPD patients.

**Disclosure**

The authors have not had any industry relationships for the past 2 years and do not have any conflict of interest in this work.

**References**


